Journal of Pharmaceutical Research
DOI: https://doi.org/10.18579/jopcr/v25.i2.128
Year: 2026, Volume: 25, Issue: 2, Pages: 85-97
Review Article
Jayesh H Patil1*, Dipali J Khairnar1, Samiksha S Donode1, Roshani R Deore2, Ashishkumar M Panpatil3, Megha S Pawar4, Avinash G Paikrao1, Dinesh N Saravate1
1Research Scholar, Department of Pharmacology, KBHSS Trust's Institute of Pharmacy, Malegaon, Nashik, Maharashtra, India
2Research Scholar, Department of Pharmaceutical Quality Assurance, STES's Smt. Kashibai Navale College of Pharmacy, Kondhwa, Pune, Maharashtra, India
3Research Scholar, Department of Pharmaceutical Quality Assurance, MET Institute of Pharmacy, Nashik, Maharashtra, India
4Research scholar, Department of Pharmacology, SSS's Divine College Pharmacy, Nampur Road, Satana, Nashik, Maharashtra, India
*Corresponding Author
Email: [email protected]
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as important therapeutic agents in type 2 diabetes mellitus (T2DM) and obesity, with benefits extending beyond glycaemic control and weight reduction. Growing preclinical and clinical evidence indicates that GLP-1RAs exert significant anti-inflammatory and antioxidant effects through mechanisms that are partly independent of their glucose-lowering actions. This review comprehensively examines the molecular pathways underlying these pleiotropic effects and highlights their translational relevance across multiple organ systems. GLP-1RAs modulate inflammatory Signalling by inhibiting nuclear factor-kappa B (NF-κB) activation and suppressing NLRP3 inflammasome activity through cyclic AMP–protein kinase A (cAMP–PKA)-mediated pathways, thereby reducing the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. In parallel, GLP-1RAs enhance cellular antioxidant defenses by activating the Nrf2/Keap1 pathway, inhibiting NADPH oxidase activity, and improving mitochondrial function, thereby reducing oxidative stress and lipid peroxidation. These effects contribute to cardioprotective, hepatoprotective, renoprotective, and neuroprotective outcomes observed in experimental and clinical studies. Furthermore, this review integrates current biomarker evidence with mechanistic insights to provide a comprehensive overview of the interconnected inflammatory and oxidative stress pathways targeted by GLP-1RAs. Collectively, these findings support the expanding therapeutic potential of GLP-1RAs in chronic inflammatory and metabolic disorders, including non-alcoholic steatohepatitis, chronic kidney disease, neurodegenerative diseases, and cardiovascular complications.
Keywords: GLP-1 receptor, agonists, Inflammation, Oxidative stress, NF-κB, Nrf2/Keap1, cAMP–PKA pathway
1. Campbell JE, Drucker DJ. Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action. Cell Metabolism. 2013; 17 (6). Available from: https://doi.org/10.1016/j.cmet.2013.04.008
2. Nauck MA. Unraveling the Science of Incretin Biology. The American Journal of Medicine. 2009; 122 (6). Available from: https://doi.org/10.1016/j.amjmed.2009.03.012
3. Cornell S. A review of GLP‐1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once‐weekly agents. Journal of Clinical Pharmacy and Therapeutics. 2020; 45 (S1). Available from: https://doi.org/10.1111/jcpt.13230
4. Sharma D, Verma S, Vaidya S, Kalia K, Tiwari V. Recent updates on GLP-1 agonists: Current advancements & challenges. Biomedicine & Pharmacotherapy. 2018; 108 Available from: https://doi.org/10.1016/j.biopha.2018.08.088
5. Manful CF, Fordjour E, Ikumoinein E, Abbey, Lord, Thomas R. Therapeutic Strategies Targeting Oxidative Stress and Inflammation: A Narrative Review. BioChem. 2025; 5 (4). Available from: https://doi.org/10.3390/biochem5040035
6. Świątkiewicz I, Wróblewski M, Nuszkiewicz J, Sutkowy P, Wróblewska J, Woźniak A. The Role of Oxidative Stress Enhanced by Adiposity in Cardiometabolic Diseases. International Journal of Molecular Sciences. 2023; 24 (7). Available from: https://doi.org/10.3390/ijms24076382
7. Ndisang JF, Vannacci A, Rastogi S. Oxidative Stress and Inflammation in Obesity, Diabetes, Hypertension, and Related Cardiometabolic Complications. Oxidative Medicine and Cellular Longevity. 2014; 2014 Available from: https://doi.org/10.1155/2014/506948
8. Obafemi OT, Ayeleso AO, Obafemi BA, Unuofin JO, Oladipo AO, Lebelo SL, <I>et al</I>. Computational Approach to Possible Interactions of Gliclazide with Proteins of Inflammatory, Oxidative Stress and Endoplasmic Reticulum Stress Pathways. Applied Biosciences. 2026; 5 (1). Available from: https://doi.org/10.3390/applbiosci5010013
9. Broide E, Bloch O, Ben-Yehudah G, Cantrell D, Shirin H, Rapoport MJ. GLP-1 Receptor Is Expressed in Human Stomach Mucosa. Journal of Histochemistry & Cytochemistry. 2013; 61 (9). Available from: https://doi.org/10.1369/0022155413497586
10. Farkas E, Szilvásy-Szabó A, Ruska Y, Sinkó R, Rasch MG, Egebjerg T, <I>et al</I>. Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain. Brain Structure and Function. 2021; 226 (1). Available from: https://doi.org/10.1007/s00429-020-02189-1
11. Tornehave D, Kristensen P, Rømer J, Knudsen LB, Heller RS. Expression of the GLP-1 Receptor in Mouse, Rat, and Human Pancreas. Journal of Histochemistry & Cytochemistry. 2008; 56 (9). Available from: https://doi.org/10.1369/jhc.2008.951319
12. Que Q, Guo X, Zhan L, Chen S, Zhang Z, Ni X, <I>et al</I>. The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis. Journal of Inflammation. 2019; 16 (1). Available from: https://doi.org/10.1186/s12950-019-0218-y
13. Tang S, Tang H, Su H, Wang Y, Zhou Q, Zhang Q, <I>et al</I>. Glucagon-like peptide-1 attenuates endothelial barrier injury in diabetes via cAMP/PKA mediated down-regulation of MLC phosphorylation. Biomedicine & Pharmacotherapy. 2019; 113 Available from: https://doi.org/10.1016/j.biopha.2019.108667
14. Barać M, Roganović J. GLP-1 Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects. Biology. 2025; 14 (12). Available from: https://doi.org/10.3390/biology14121650
15. Li Z, Li S, Wang N, Xue P, Li Y. Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R. Biomedicine & Pharmacotherapy. 2020; 130 Available from: https://doi.org/10.1016/j.biopha.2020.110523
16. Lin M, Xue B, Bai X. Glucagon-like Peptide-1 Receptor Dependent Signaling in Cardiovascular Health and Disease: A Mini-review. Journal of Cardiovascular Translational Research. 2026; 19 (1). Available from: https://doi.org/10.1007/s12265-026-10759-7
17. Liu J, Yang K, Xiao W, Le Y, Lang S, Zhang J, <I>et al</I>. GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner. Peptides. 2018; 106 Available from: https://doi.org/10.1016/j.peptides.2018.07.001
18. Kim Chung LT, Hosaka T, Yoshida M, Harada N, Sakaue H, Sakai T, <I>et al</I>. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochemical and Biophysical Research Communications. 2009; 390 (3). Available from: https://doi.org/10.1016/j.bbrc.2009.10.015
19. Yaribeygi H, Maleki M, Atkin SL, Jamialahmadi T, Sahebkar A. Impact of Incretin-Based Therapies on Adipokines and Adiponectin. Journal of Diabetes Research. 2021; 2021 Available from: https://doi.org/10.1155/2021/3331865
20. Lee Y-S, Jun H-S. Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control. Mediators of Inflammation. 2016; 2016 Available from: https://doi.org/10.1155/2016/3094642
21. Hur J, Kang JY, Kim YK, Lee SY, Lee HY. Glucagon-like peptide 1 receptor (GLP-1R) agonist relieved asthmatic airway inflammation via suppression of NLRP3 inflammasome activation in obese asthma mice model. Pulmonary Pharmacology & Therapeutics. 2021; 67 Available from: https://doi.org/10.1016/j.pupt.2021.102003
22. Li X, Jiang X, Jiang M, Wang Z, Zhao T, Cao S, <I>et al</I>. GLP-1RAs inhibit the activation of the NLRP3 inflammasome signaling pathway to regulate mouse renal podocyte pyroptosis. Acta Diabetologica. 2023; 61 (2). Available from: https://doi.org/10.1007/s00592-023-02184-y
23. Li Z, Feng P-P, Zhao Z-B, Zhu W, Gong J-P, Du H-M. Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 Signalling pathway. Biochemical and Biophysical Research Communications. 2019; 510 Available from: https://doi.org/10.1016/j.bbrc.2018.12.149
24. Wang X, Yang X, Qi X, Fan G, Zhou L, Peng Z, <I>et al</I>. Anti-atherosclerotic effect of incretin receptor agonists. Frontiers in Endocrinology. 2024; 15 Available from: https://doi.org/10.3389/fendo.2024.1463547
25. Yang L, Chen L, Li D, Xu H, Chen J, Min X, <I>et al</I>. Effect of GLP‐1/GLP‐1R on the Polarization of Macrophages in the Occurrence and Development of Atherosclerosis. Mediators of Inflammation. 2021; 2021 (1). Available from: https://doi.org/10.1155/2021/5568159
26. Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Therapeutic Advances in Endocrinology and Metabolism. 2024; 15 Available from: https://doi.org/10.1177/20420188231222367
27. Luna-Marco C, De Marañon AM, Hermo-Argibay A, Rodriguez-Hernandez Y, Hermenejildo J, Fernandez-Reyes M, <I>et al</I>. Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes. Redox Biology. 2023; 66 Available from: https://doi.org/10.1016/j.redox.2023.102849
28. Kamath S, Chan NSL, Joyce P. GLP‐1 agonists and the gut microbiome: A bidirectional relationship. British Journal of Clinical Pharmacology. 2026; 92 (5). Available from: https://doi.org/10.1002/bcp.70487
29. Diz-Chaves Y, Mastoor Z, Spuch C, González-Matías LC, Mallo F. Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. International Journal of Molecular Sciences. 2022; 23 (17). Available from: https://doi.org/10.3390/ijms23179583
30. Ghosh P, Fontanella RA, Scisciola L, Pesapane A, Taktaz F, Franzese M, <I>et al</I>. Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists. Theranostics. 2023; 13 (14). Available from: https://doi.org/10.7150/thno.86831
31. Lv R, Zhao Y, Wang X, He Y, Dong N, Min X, <I>et al</I>. GLP-1 analogue liraglutide attenuates CIH-induced cognitive deficits by inhibiting oxidative stress, neuroinflammation, and apoptosis via the Nrf2/HO-1 and MAPK/NF-κB signaling pathways. International Immunopharmacology. 2024; 142 Available from: https://doi.org/10.1016/j.intimp.2024.113222
32. Kalsoom U-E, Jin J, Meng W, Su Y, Wu C, Wu Q. The role of NADPH oxidases in central nervous system regulation of hypertension: Mechanisms and therapeutic insights. Biomedicine & Pharmacotherapy. 2026; 196 Available from: https://doi.org/10.1016/j.biopha.2026.119096
33. Youssef N, Noureldein M, Njeim R, Ghadieh H, Harb F, Azar S, <I>et al</I>. Reno-Protective Effect of GLP-1 Receptor Agonists in Type1 Diabetes: Dual Action on TRPC6 and NADPH Oxidases. Biomedicines. 2021; 9 (10). Available from: https://doi.org/10.3390/biomedicines9101360
34. Dasgupta T, Bhayani H, Ghoshdastidar K, Viswanathan K, Jain M. GLP-1 and the brain’s powerhouse: a new perspective on the role of mitochondria in neuroprotection. Metabolic Brain Disease. 2026; 41 (1). Available from: https://doi.org/10.1007/s11011-026-01839-3
35. Leeming PJ, Mercuri-Svik J, Stojanovski D. From Biogenesis to Breakdown: How Protein Biogenesis and Quality Control Failures Drive Mitochondrial Disease. Molecular and Cellular Biology. 2026; 46 (1). Available from: https://doi.org/10.1080/10985549.2025.2566671
36. Lee J, You JH, Park HJ, Roh J-L, Paek SH. Metabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications. Current Obesity Reports. 2026; 15 (1). Available from: https://doi.org/10.1007/s13679-026-00709-4
37. Samy EM, Shaaban EA. Liraglutide Ameliorates Gamma Radiation-Induced Hepatic Damage in Rats: The Role of an Autophagy Flux Activation via LKB1/AMPK/mTOR Axis. Archives of Medical Research. 2026; 57 (2). Available from: https://doi.org/10.1016/j.arcmed.2025.103296
38. Wei H, Ye L, Li M, Huang S, Mo Z. Effect of GLP-1 RA and SGLT2I on Biomarkers of Oxidative Stress in T2DM: A Systematic Review and Meta-analysis. Journal of the Endocrine Society. 2025; 9 (8). Available from: https://doi.org/10.1210/jendso/bvaf075
39. Zhang X, Jiang J, Xu J, Chen J, Gu Y, Wu G. Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes. BMC Musculoskeletal Disorders. 2024; 25 (1). Available from: https://doi.org/10.1186/s12891-024-07640-6
40. Sheahan KH, Wahlberg EA, Gilbert MP. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgraduate Medical Journal. 2020; 96 (1133). Available from: https://doi.org/10.1136/postgradmedj-2019-137186
41. Lv X, Dong Y, Hu L, Lu F, Zhou C, Qin S. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review. Endocrinology, Diabetes & Metabolism. 2020; 3 (3). Available from: https://doi.org/10.1002/edm2.163
42. Petit J-M, Vergès B. GLP-1 receptor agonists in NAFLD. Diabetes & Metabolism. 2017; 43 Available from: https://doi.org/10.1016/s1262-3636(17)30070-8
43. Granata A, Maccarrone R, Anzaldi M, Leonardi G, Pesce F, Amico F, <I>et al</I>. GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art. Clinical Kidney Journal. 2022; 15 (9). Available from: https://doi.org/10.1093/ckj/sfac069
44. Michos ED, Bakris GL, Rodbard HW, Tuttle KR. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection. American Journal of Preventive Cardiology. 2023; 14 Available from: https://doi.org/10.1016/j.ajpc.2023.100502
45. D’Marco L, Morillo V, Gorriz JL, Suarez MK, Nava M, Ortega Á, <I>et al</I>. SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence. Journal of Diabetes Research. 2021; 2021 Available from: https://doi.org/10.1155/2021/9032378
46. Szekeres Z, Nagy A, Jahner K, Szabados E. Impact of Selected Glucagon-like Peptide-1 Receptor Agonists on Serum Lipids, Adipose Tissue, and Muscle Metabolism—A Narrative Review. International Journal of Molecular Sciences. 2024; 25 (15). Available from: https://doi.org/10.3390/ijms25158214
47. Athauda D, Greig NH, Meissner WG, Foltynie T, Gandhi S. The promise of GLP-1 receptor agonists for neurodegenerative diseases. Journal of Clinical Investigation. 2026; 136 (4). Available from: https://doi.org/10.1172/jci194745
48. Cheng D, Yang S, Zhao X, Wang G. The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases. Drug Design, Development and Therapy. 2022; Volume 16 Available from: https://doi.org/10.2147/dddt.s348055
49. Marzook A, Tomas A, Jones B. The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells. Frontiers in Endocrinology. 2021; 12 Available from: https://doi.org/10.3389/fendo.2021.678055
50. Rea N, Ramdass PVAK. GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus: a systematic review and meta-analysis of preclinical studies. Frontiers in Clinical Diabetes and Healthcare. 2025; 6 Available from: https://doi.org/10.3389/fcdhc.2025.1579961
51. Bray JJH, Foster‐Davies H, Salem A, Hoole AL, Obaid DR, Halcox JPJ, <I>et al</I>. Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials. Diabetes, Obesity and Metabolism. 2021; 23 (8). Available from: https://doi.org/10.1111/dom.14399
52. Bilgin E, Venerito V, Bogdanos DP. Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions. Autoimmunity Reviews. 2025; 24 (9). Available from: https://doi.org/10.1016/j.autrev.2025.103864
53. Moiz A, Filion KB, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. eClinicalMedicine. 2025; 86 Available from: https://doi.org/10.1016/j.eclinm.2025.103363
54. Pawar M, Patil C, Fakir Z, Pagar D, Mahajan S. GLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives. BioMed Target Journal. 2025; 3 (2). Available from: https://doi.org/10.59786/bmtj.322
© 2026 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Subscribe now for latest articles and news.
